Learning interpretable disease self-representations for drug repositioning

09/14/2019
by   Fabrizio Frasca, et al.
14

Drug repositioning is an attractive cost-efficient strategy for the development of treatments for human diseases. Here, we propose an interpretable model that learns disease self-representations for drug repositioning. Our self-representation model represents each disease as a linear combination of a few other diseases. We enforce the proximity between diseases to preserve the geometric structure of the human phenome network - a domain-specific knowledge that naturally adds relational inductive bias to the disease self-representations. We prove that our method is globally optimal and show results outperforming state-of-the-art drug repositioning approaches. We further show that the disease self-representations are biologically interpretable.

READ FULL TEXT

page 1

page 2

page 3

page 4

page 6

page 7

page 8

page 9

02/08/2022

Deep learning for drug repurposing: methods, databases, and applications

Drug development is time-consuming and expensive. Repurposing existing d...
07/14/2020

Clinical connectivity map for drug repurposing: using laboratory tests to bridge drugs and diseases

Drug repurposing has attracted increasing attention from both the pharma...
04/30/2020

Modeling Pharmacological Effects with Multi-Relation Unsupervised Graph Embedding

A pharmacological effect of a drug on cells, organs and systems refers t...
11/15/2012

Ontology Based Information Extraction for Disease Intelligence

Disease Intelligence (DI) is based on the acquisition and aggregation of...
06/13/2019

Interpretable ICD Code Embeddings with Self- and Mutual-Attention Mechanisms

We propose a novel and interpretable embedding method to represent the i...
04/16/2020

Network-principled deep generative models for designing drug combinations as graph sets

Combination therapy has shown to improve therapeutic efficacy while redu...
12/09/2016

Measuring Adverse Drug Effects on Multimorbity using Tractable Bayesian Networks

Managing patients with multimorbidity often results in polypharmacy: the...